MAPT and Alzheimer disease: Supporting this, we found that a higher tau hub ratio at baseline predicted faster subsequent tau accumulation in patients with symptomatic AD (ADNI: β = 0.347, p = 0.006, Fig. 4D, right panel; BioFINDER: β = 0.668, p = 0.002, Fig. 4E, right panel), controlling for sex, education and diagnosis.